Velcade: study of real-life use FRESH-PEF3195-en Cécile DROZ-PERROTEAU Velcade: study of real-life use VESUVE (beta) FRESH-PEF3195-en 3195 FRESH-PEF3195 Annie FOURRIER-REGLAT Nicholas MOORE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) UNIVERSITE DE BORDEAUX Epidemiology France Portal (PEF) JANSSEN CILAG (JANSSEN - JOHNSON & JOHNSON - JOHNSON & JOHNSON INNOVATIVE MEDICINE) null Annie;FOURRIER-REGLAT Nicholas;MOORE Multiple myeloma Velcade® Bortezomib survival conditions of use pharmacoepidemiology cohort Department of Pharmacology Bordeaux Oncology Hematology Healthcare system determinants: Use of care Healthcare system determinants The objectives are to evaluate the response and survival of patients treated by Velcade®, to describe the population of patients initiating treatment with Velcade® (socio-demographic data, previous treatments, indication), and describe the conditions of use Velcade® (dose, number and frequency of treatment cycles) null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Patients initiating Bortezomib treatment between 1 May 2004 and April 30 2006 (whether or not treatment is continued); Patient unexposed to bortezomib, including during a clinical trial or temporary use authorization; Patient followed by a hospital physician having agreed to participate in the study; Patient not participating in a clinical trial; Patient not objecting to data collection Clinical data Health event/morbidity Health event/mortality Health care consumption and services Other Through independent healthcare practitioners Through organizations (health services or institutions schools businesses etc.) [500-1000[ individuals Converting or copying information into a structured record Observational Study Observational Study 1310 patients identified by hospital pharmacists, including 924 patients for whom their physician agreed to participate in the study, and 793 patients were eligible for follow up. Unknown To be defined Ownership of study data was the subject of an agreement between the University of Bordeaux Segalen and the pharmaceutical company. Access on specific project only